Aclaris Therapeutics (ACRS) Stock Forecast & Price Target

$1.05

-0.02 (-1.87%)

(As of 12/29/2023 ET)

Aclaris Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 8 Analyst Ratings

Analysts' Consensus Price Target

$23.17
2,106.35% Upside

High Forecast	$38.00
Average Forecast	$23.17
Low Forecast	$9.00

Type	Current Forecast 12/31/22 to 12/31/23	1 Month Ago 12/1/22 to 12/1/23	3 Months Ago 10/2/22 to 10/2/23	1 Year Ago 12/31/21 to 12/31/22
Consensus Rating	Moderate Buy	Moderate Buy	Buy	Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	4 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$23.17	$23.17	$30.20	$28.67
Predicted Upside	2,106.35% Upside	308.37% Upside	308.88% Upside	83.29% Upside

Get Aclaris Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter.

ACRS Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ACRS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Aclaris Therapeutics Stock vs. The Competition

Type	Aclaris Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.50	2.67	2.49
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	2,106.35% Upside	2,167.34% Upside	6.98% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Ratings and Stock Forecasts

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/29/2023	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$9.00	+672.53%
12/18/2023	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral
11/13/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Smith Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
11/13/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold
11/13/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Lugo Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
10/3/2023	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$22.00	+238.98%
3/7/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$25.00 ➝ $21.00	+183.40%
3/7/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$32.00 ➝ $29.00	+310.18%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 10:44 PM ET.

ACRS Price Target - Frequently Asked Questions

What is Aclaris Therapeutics's consensus rating and price target?: According to the issued ratings of 8 analysts in the last year, the consensus rating for Aclaris Therapeutics stock is Moderate Buy based on the current 4 hold ratings and 4 buy ratings for ACRS. The average twelve-month price prediction for Aclaris Therapeutics is $23.17 with a high price target of $38.00 and a low price target of $9.00. Learn more on ACRS's analyst rating history.
Do Wall Street analysts like Aclaris Therapeutics more than its competitors?: Analysts like Aclaris Therapeutics less than other Medical companies. The consensus rating score for Aclaris Therapeutics is 2.50 while the average consensus rating score for medical companies is 2.67. Learn more on how ACRS compares to other companies.
Is Aclaris Therapeutics being downgraded by Wall Street analysts?: Over the previous 90 days, Aclaris Therapeutics's stock had 3 downgrades by analysts.

Does Aclaris Therapeutics's stock price have much upside?: According to analysts, Aclaris Therapeutics's stock has a predicted upside of 301.22% based on their 12-month stock forecasts.
What analysts cover Aclaris Therapeutics?: Aclaris Therapeutics has been rated by Cantor Fitzgerald, Evercore ISI, HC Wainwright, Leerink Partnrs, Stifel Nicolaus, and William Blair in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:ACRS) was last updated on 12/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial